Marco Meglio

Half of the treated individuals saw a reduction of more than 50% in the number and duration of epileptic spasms following treatment with CER-0001, a ketogenic therapy.

The agency requested modifications to the REMS program, seeking validation of patients’ meningococcal vaccination status and prophylactic administration of antibodies prior to giving ravulizumab treatment.

The director of the ALS Clinic at Allegheny Health Network provided perspective on the advancements in the treatment and management of adult-onset spinal muscular atrophy.

An expert panel discusses diagnosis and treatment of patients with Parkinson disease, exploring the challenges in managing dyskinesia, finding a balance between OFF episodes and ON time, and current and emerging treatment options.

More than a 40% improvement in ON time without troublesome dyskinesia occurred as patients had their treatment titrated.

A group of esteemed panelists discussed the important values neurology department directors and educators should prioritize when teaching students of the future. [WATCH TIME: 6 minutes]

A trio of former and current neurology department directors discussed ways in which residency and fellowship programs may change as technology and therapeutic capabilities continue to expand. [WATCH TIME: 8 minutes]

When compared with levodopa-sparing agents, treatment levodopa alone resulted in significantly better patient-rated Parkinson’s Disease Questionnaire activities of daily living and summary index scores.

Findings of a new novel genetic risk factor could inform future GBA1 clinical trials, improving patient stratification and the odds of designing trials that are more likely to produce meaningful and actionable answers.

A panel of former AUPN presidents detailed how advances in neurology have changed the way the clinical specialty is taught, and why collaboration among leadership remains vital to creating an effective neurology department. [WATCH TIME: 7 minutes]

Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.

Swallowing difficulties, a major concern for patients with Parkinson disease, occurred rarely in the study, and were spontaneously resolved over time.

The distinguished investigator at the National Institutes of Health provided insight on the topic of globalizing Parkinson disease genetics, and how it may lead to potential disease-modifying therapies.

The group of experts provided perspectives on the shift in how residency programs are developed and laid out, as well as efforts to increase the number of young neurologists in the field.

Patients treated with the probiotic saw benefits in non-motor symptoms such as sleep, fatigue, and gastrointestinal outcomes.

Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.

After a year of treatment, patients showed significant improvements in ON time without troublesome dyskinesia, with more apparent effects observed in the high-dose group.

Significant thinning of GCIPL and INL appeared earlier in individuals with Parkinson disease, being discernible several years prior to clinical presentation.

With limited options available in perimenstrual catamenial epilepsy, a phase 4 study seeks to understand whether an FDA-approved agent for focal onset seizures can effectively treat women with difficult-to-manage disease.

Time to the first clinical event was significantly extended in the teriflunomide arm compared with placebo, in both the unadjusted and adjusted analysis.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicole Fowler. [LISTEN TIME: 23 minutes]

Autologous hematopoietic stem cell transplant was associated with a higher rate of recovery from disability than fingolimod and natalizumab, especially during the initial year posttreatment.

Over a 3-treatment cycle, no new clinically significant safety observations were found, with significant dose-dependent increases in frataxin in muscle mRNA expression.

The associate staff member in the department of neurology at Cleveland Clinic provided perspective on a recently published phase 1 study assessing deep brain stimulation in individuals with chronic poststroke hemiparesis.

Among a cohort of more than 70 individuals with MS, only 1 relapse occurred while on eculizumab, with significant reductions in immunosuppressive use observed.

Over a 28-day period, no adverse events led to study drug withdrawal, with decreased appetite as the most common treatment-related AE observed in the highest dosed cohort.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Erin Furr-Stimming, MD, FAAN, FANA. [LISTEN TIME: 11 minutes]

Over a 48-week stretch, a composite end point analysis suggested a survival treatment benefit with edaravone, further supporting its use in patients with ALS.

Alex Whiting, MD, director of epilepsy surgery at Allegheny Health Network, discussed the challenges with drug-resistant epilepsy, and how clinicians can initiate conversations about potential options for their patients.

In 2 pivotal phase 3 trials, atogepant met its primary end point of superior reduction in monthly migraine days vs placebo, with consistent safety throughout.